Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA-CAR-T in CEA+ Advanced Solid Tumors
NCT06013111Phase 1Recruiting
- Sponsor
- China Medical University
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by China Medical University. Primary endpoint: Dose-limiting toxicity at 21 days. Started Oct 2023; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06013111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013111.